Azione DISCOVERY LABORATORIES, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati
Strumento inattivo

Altre lingue Discovery Laboratories, Inc. Nasdaq

Azioni

US2546684034

Prezzo di chiusura Nasdaq
Altri mercati azionari
- USD - Grafico intraday di Discovery Laboratories, Inc.
16/04 Windtree Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023 CI
10/04 Transcript : Windtree Therapeutics, Inc. - Shareholder/Analyst Call

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Windtree Therapeutics Regains Compliance with Nasdaq
Windtree Therapeutics : April'24 Corporate Presentation
Windtree Therapeutics Announces Reverse Stock Split
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
Windtree Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
North American Morning Briefing : Stock Futures -2-
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals
Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
Windtree Therapeutics, Inc. announced that it has received $1.5 million in funding
Windtree Therapeutics, Inc. acquired All of the assets of Varian Biopharmaceuticals, Inc.
Windtree Therapeutics, Inc. announced that it expects to receive $1.5 million in funding
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Interim Chief Financial Officer and Principal Financial Officer
Windtree Therapeutics, Inc. Announces Resignation of John A. Tattory as Principal Financial Officer
Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Windtree Therapeutics, Inc. Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
Windtree Therapeutics Engages Ladenburg to Evaluate Strategic Alternatives
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
WINDTREE THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH LEE'S PHARMACEUTICALS TO DEVELOP AND COMMERCIALIZE ISTAROXIME, DUAL MECHANISM SERCA2A ACTIVATORS AND ROSTAFUROXIN FOR GREATER CHINA, ASIA PACIFIC REGION
Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione WINT
  4. Azione
  5. Notizie Discovery Laboratories, Inc.
  6. Altre lingue